|
|
|
Mural Oncology Plc (NASDAQ: MURA) |
|
Mural Oncology Plc
MURA's Fundamental analysis
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
|
Mural Oncology Plc's sales fell
in III. Quarter 2024 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
growth of revenues by 9.72 %
Mural Oncology Plc net loss decreased from $-51 millions, to $-32 millions in III. Quarter 2024,
• More on MURA's Growth
|
|
Mural Oncology Plc
realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 0.61 in trailing twelve-month period. |
| Company |
| - |
|
PE TTM
|
| Industry |
|
- |
|
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.28.
• More on MURA's Valuation
|
|
|
|
|
Mural Oncology Plc
realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 0.61 in trailing twelve-month period. |
| Company |
| - |
|
PE TTM
|
| Industry |
|
- |
|
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.28.
Mural Oncology Plc Price to Book Ratio is at 0.39 lower than Industry Avg. of 81.16. and higher than S&P 500 Avg. of 0.01
• More on MURA's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
